四环医药(00460.HK)：轩竹生物尚未就H股于联交所主板上市及买卖向联交所提出申请

Core Viewpoint - The announcement by Sihuan Pharmaceutical (00460.HK) regarding the proposal for full circulation of H-shares for Xuan Bamboo Biotechnology, which involves converting 357,245,794 unlisted shares into H-shares, representing approximately 68.9733% of the total issued shares as of November 14, 2025 [1] Group 1 - Xuan Bamboo Biotechnology submitted a filing application to the China Securities Regulatory Commission on November 17, 2025, for the conversion of shares [1] - The conversion will be on a one-to-one basis for six shareholders [1] - As of the announcement date, Xuan Bamboo has not yet applied for the listing and trading of these H-shares on the Hong Kong Stock Exchange [1]